Interfering with lncRNA FOXD2-AS1 can inhibit the proliferation, invasion, and migration of breast cancer cells, promote cell apoptosis, improve the chemical sensitivity of MCF-7/ADR cells, and inhibit the PI3K/AKT signaling pathway. Here, FOXD2 is linked to breast cancer.